Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$14.74
$14.62
$6.38
$14.76
$1.87B0.193.08 million shs3.45 million shs
Concordia International Corp. stock logo
CXR
Concordia International
C$0.00
C$19.02
C$417.00
C$1.22BN/A4,054 shs73,541 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00%0.00%0.00%0.00%0.00%
Concordia International Corp. stock logo
CXR
Concordia International
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$14.74
$14.62
$6.38
$14.76
$1.87B0.193.08 million shs3.45 million shs
Concordia International Corp. stock logo
CXR
Concordia International
C$0.00
C$19.02
C$417.00
C$1.22BN/A4,054 shs73,541 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00%0.00%0.00%0.00%0.00%
Concordia International Corp. stock logo
CXR
Concordia International
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00
N/AN/AN/A
Concordia International Corp. stock logo
CXR
Concordia International
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$15K124,613.93N/AN/A$3.09 per share4.77
Concordia International Corp. stock logo
CXR
Concordia International
C$569.62M0.00N/A5.85C$6.08 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BELLUS Health Inc. stock logo
BLU
BELLUS Health
-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/A
Concordia International Corp. stock logo
CXR
Concordia International
N/AC$351.680.07N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/A
Concordia International Corp. stock logo
CXR
Concordia International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/A
33.42
33.42
Concordia International Corp. stock logo
CXR
Concordia International
457.02
2.10
1.66

Institutional Ownership

CompanyInstitutional Ownership
BELLUS Health Inc. stock logo
BLU
BELLUS Health
90.37%
Concordia International Corp. stock logo
CXR
Concordia International
N/A

Insider Ownership

CompanyInsider Ownership
BELLUS Health Inc. stock logo
BLU
BELLUS Health
24.17%
Concordia International Corp. stock logo
CXR
Concordia International
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
BELLUS Health Inc. stock logo
BLU
BELLUS Health
74126.81 million96.16 millionNot Optionable
Concordia International Corp. stock logo
CXR
Concordia International
22,50048.91 millionN/ANot Optionable

Recent News About These Companies

Productivity Suite - Students
Concordia 2024 Kicks Off in New York City
STUDENTS FROM ABROAD
University or college transfer
Anthropology and Sociology (BA)
Hospital brings back X-ray walk-in-only services
Concordia College inaugurates President Colin Irvine
Entrance awards
BELLUS Health stock logo

BELLUS Health NASDAQ:BLU

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Concordia International stock logo

Concordia International TSE:CXR

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.